https://www.biopharmawatch.com/news/STE/steris-raises-dividend-to-0-69-per-share BiopharmaWatch en 2026-07-30T20:30:00.000Z STERIS Raises Dividend to $0.69 per share https://www.biopharmawatch.com/news/CLLS/cellectis-second-quarter-financial-results-2026 BiopharmaWatch en 2026-07-30T20:30:00.000Z Cellectis to Report Second Quarter Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/COO/coopercompanies-release-date-third-quarter-2026 BiopharmaWatch en 2026-07-30T20:15:00.000Z CooperCompanies Announces Release Date for Third Quarter 2026 https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-q2-2026-results-clinical-milestones BiopharmaWatch en 2026-07-30T20:05:00.000Z Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-canaccord-growth-conference-2023 BiopharmaWatch en 2026-07-30T20:05:00.000Z Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference https://www.biopharmawatch.com/news/SRTS/sensus-healthcare-q2-2026-results-conference-call BiopharmaWatch en 2026-07-30T20:05:00.000Z Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026 https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-q2-2026-investor-update-call BiopharmaWatch en 2026-07-30T20:05:00.000Z Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call https://www.biopharmawatch.com/news/PRTA/prothena-report-q2-2026-results-august-6 BiopharmaWatch en 2026-07-30T20:05:00.000Z Prothena to Report Second Quarter 2026 Financial Results on August 6 https://www.biopharmawatch.com/news/GH/guardant-health-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance https://www.biopharmawatch.com/news/FLGT/fulgent-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Fulgent Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ILMN/illumina-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 https://www.biopharmawatch.com/news/CSTL/castle-biosciences-q2-2026-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Castle Biosciences Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/PEN/penumbra-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Penumbra, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CV/capsovision-second-quarter-2026-results-release BiopharmaWatch en 2026-07-30T20:05:00.000Z CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/ABVX/abivax-positive-pre-nda-interaction-fda-obefazimod BiopharmaWatch en 2026-07-30T20:05:00.000Z Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T20:05:00.000Z Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 https://www.biopharmawatch.com/news/SYK/stryker-second-quarter-2026-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Stryker reports second quarter 2026 operating results https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 https://www.biopharmawatch.com/news/MYGN/myriad-genetics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:05:00.000Z Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability https://www.biopharmawatch.com/news/DXCM/dexcom-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:02:00.000Z Dexcom Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CERS/cerus-corporation-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Cerus Corporation Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-q2-2026-financial-results-webcast BiopharmaWatch en 2026-07-30T20:01:00.000Z Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/CDNA/caredx-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z CareDx Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/amgen-announces-2026-third-quarter-dividend BiopharmaWatch en 2026-07-30T20:01:00.000Z AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND https://www.biopharmawatch.com/news/GRAL/grail-presentation-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-30T20:01:00.000Z GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-corporate-update-q2-2026-results BiopharmaWatch en 2026-07-30T20:01:00.000Z PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NSPR/inspiremd-appoints-kathleen-kennedy-svp-sales-marketing BiopharmaWatch en 2026-07-30T20:01:00.000Z InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing https://www.biopharmawatch.com/news/ANNX/annexon-secures-credit-facility-200-million BiopharmaWatch en 2026-07-30T20:01:00.000Z Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance https://www.biopharmawatch.com/news/ALHC/alignment-healthcare-q2-2026-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-business-update-q2-2026 BiopharmaWatch en 2026-07-30T20:01:00.000Z Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/KROS/keros-therapeutics-milestone-payment-takeda BiopharmaWatch en 2026-07-30T20:01:00.000Z Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda https://www.biopharmawatch.com/news/PRAX/praxis-precision-medicines-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/XENE/xenon-report-q2-2026-financial-results BiopharmaWatch en 2026-07-30T20:01:00.000Z Xenon to Report Q2 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/MDXH/mdxhealth-q2-2026-financial-results-release BiopharmaWatch en 2026-07-30T20:00:00.000Z Mdxhealth to Release Second Quarter 2026 Financial Results on August 13 https://www.biopharmawatch.com/news/IVA/inventiva-preliminary-financial-results-h1-2026 BiopharmaWatch en 2026-07-30T20:00:00.000Z Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹ https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-private-placement-nasdaq BiopharmaWatch en 2026-07-30T18:23:00.000Z 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/SRXH/srx-global-acquires-shares-jersey-mikes-ipo BiopharmaWatch en 2026-07-30T18:04:00.000Z SRX Global Acquires Shares in Jersey Mike’s $1 Billion Initial Public Offering https://www.biopharmawatch.com/news/AMGN/repatha-cmuh-favorable-opinion-cardiovascular-risk BiopharmaWatch en 2026-07-30T16:45:00.000Z AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC https://www.biopharmawatch.com/news/ELV/elevance-health-connected-cancer-care-model BiopharmaWatch en 2026-07-30T16:00:00.000Z Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey https://www.biopharmawatch.com/news/LEXX/lexaria-reverse-stock-split-effective-date BiopharmaWatch en 2026-07-30T15:02:41.000Z Lexaria Announces Effective Date for Reverse Stock Split https://www.biopharmawatch.com/news/SNY/sanofi-semi-annual-financial-report-2026 BiopharmaWatch en 2026-07-30T13:38:00.000Z Communiqué de presse : Rapport financier semestriel 2026 de Sanofi https://www.biopharmawatch.com/news/SNY/sanofi-half-year-financial-report-2026 BiopharmaWatch en 2026-07-30T13:38:00.000Z Press Release: Sanofi’s half-year financial report for 2026 https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-deramiocel-fda-update BiopharmaWatch en 2026-07-30T13:30:00.000Z Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel https://www.biopharmawatch.com/news/HNGE/hinge-health-lowers-fall-risk-adults-65 BiopharmaWatch en 2026-07-30T13:05:00.000Z Study finds Hinge Health significantly lowers fall risk for adults aged 65+ https://www.biopharmawatch.com/news/CODX/co-diagnostics-q2-2026-earnings-release-webcast BiopharmaWatch en 2026-07-30T13:00:00.000Z Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast https://www.biopharmawatch.com/news/BMRN/biomarin-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-30T13:00:00.000Z BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET https://www.biopharmawatch.com/news/CVS/cvs-health-wins-us-customer-experience-awards-2026 BiopharmaWatch en 2026-07-30T13:00:00.000Z CVS Health® named Overall Winner and wins four gold awards at 2026 US Customer Experience Awards https://www.biopharmawatch.com/news/IMNN/imunon-phase-3-ovation-3-trial-update BiopharmaWatch en 2026-07-30T13:00:00.000Z IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer https://www.biopharmawatch.com/news/CVM/cel-sci-multikine-phase-3-data-publication BiopharmaWatch en 2026-07-30T12:31:00.000Z Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients https://www.biopharmawatch.com/news/AIDX/20-20-biolabs-investor-webinar-east-asia-strategy BiopharmaWatch en 2026-07-30T12:31:00.000Z 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour https://www.biopharmawatch.com/news/AMGN/amgen-repatha-chmp-opinion-broader-use BiopharmaWatch en 2026-07-30T12:30:00.000Z LA OPINIÓN FAVORABLE DEL CHMP RESPALDA UN USO MÁS AMPLIO DE REPATHA® DE AMGEN https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-q2-2026-business-update BiopharmaWatch en 2026-07-30T12:30:00.000Z Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 https://www.biopharmawatch.com/news/VERU/veru-fireside-chat-canaccord-growth-conference BiopharmaWatch en 2026-07-30T12:30:00.000Z Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference https://www.biopharmawatch.com/news/CMND/clearmind-positive-safety-findings-cmnd-100-trial BiopharmaWatch en 2026-07-30T12:30:00.000Z Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial https://www.biopharmawatch.com/news/IRON/disc-medicine-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T12:30:00.000Z Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CING/cingulate-phase-3-adhd-trial-results-publication BiopharmaWatch en 2026-07-30T12:30:00.000Z Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology https://www.biopharmawatch.com/news/LITS/lite-strategy-repurchases-shares-increasing-litecoin-backing BiopharmaWatch en 2026-07-30T12:30:00.000Z Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share https://www.biopharmawatch.com/news/LXRX/lexicon-pharmaceuticals-q2-2026-results-release BiopharmaWatch en 2026-07-30T12:30:00.000Z Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/RKTO/rocket-one-nasa-agreement-space-ai-technology BiopharmaWatch en 2026-07-30T12:19:00.000Z Rocket One and NASA Reach Agreement to Advance Space AI Technology https://www.biopharmawatch.com/news/VNRX/volition-advances-nuq-nets-platform-commercialization BiopharmaWatch en 2026-07-30T12:17:00.000Z Volition Advances Nu.Q® NETs Platform Towards Commercialization https://www.biopharmawatch.com/news/HYPR/hyperfine-peer-reviewed-publications-swoop-system BiopharmaWatch en 2026-07-30T12:15:00.000Z Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care https://www.biopharmawatch.com/news/AMGN/repatha-chmp-positive-opinion-amgen BiopharmaWatch en 2026-07-30T12:15:00.000Z POZYTYWNA OPINIA CHMP OTWIERA DROGĘ DO SZERSZEGO STOSOWANIA LEKU REPATHA® FIRMY AMGEN PRZED WYSTĄPIENIEM PIERWSZEGO ZAWAŁU SERCA LUB UDARU MÓZGU https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-acesot-1051-update BiopharmaWatch en 2026-07-30T12:09:46.921Z Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 https://www.biopharmawatch.com/news/SVRA/savara-patent-grants-molbreevi-europe-australia BiopharmaWatch en 2026-07-30T12:05:00.000Z Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-q2-financial-results-conference-call BiopharmaWatch en 2026-07-30T12:05:00.000Z Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/ABBV/juvederm-day-returns-us-august-19 BiopharmaWatch en 2026-07-30T12:00:00.000Z JUVÉDERM® Day Returns to U.S. on August 19 https://www.biopharmawatch.com/news/ALNY/alnylam-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress https://www.biopharmawatch.com/news/LCTX/lineage-cell-therapeutics-q2-2026-report BiopharmaWatch en 2026-07-30T12:00:00.000Z Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 https://www.biopharmawatch.com/news/NTRA/natera-second-quarter-results-august-2026 BiopharmaWatch en 2026-07-30T12:00:00.000Z Natera to Report its Second Quarter Results on August 6, 2026 https://www.biopharmawatch.com/news/CRIS/curis-doses-first-five-patients-takeaim-cll-study BiopharmaWatch en 2026-07-30T12:00:00.000Z Curis Doses First Five Patients in TakeAim CLL Study https://www.biopharmawatch.com/news/ECOR/electrocore-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/ENLV/enlivex-treasury-update-rain-volume-growth BiopharmaWatch en 2026-07-30T12:00:00.000Z Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T12:00:00.000Z Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MIRA/mira-pharmaceuticals-mira-55-skny-1-ind-studies BiopharmaWatch en 2026-07-30T12:00:00.000Z MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies https://www.biopharmawatch.com/news/VRCA/verrica-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T12:00:00.000Z Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 https://www.biopharmawatch.com/news/IMMP/immutep-quarterly-activities-report-q4-fy26 BiopharmaWatch en 2026-07-30T12:00:00.000Z Immutep Quarterly Activities Report Q4 FY26 https://www.biopharmawatch.com/news/EVMN/evommune-phase-2b-trial-evo756-migraine-prophylaxis BiopharmaWatch en 2026-07-30T12:00:00.000Z Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-conference-call-august-2026 BiopharmaWatch en 2026-07-30T12:00:00.000Z Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/PETS/petmed-express-report-q1-fiscal-year-2027 BiopharmaWatch en 2026-07-30T12:00:00.000Z PetMed Express, Inc. to Report First Quarter Fiscal Year 2027 Financial Results on Thursday, August 13, 2026 https://www.biopharmawatch.com/news/PYPD/polypid-second-quarter-2026-results-report BiopharmaWatch en 2026-07-30T12:00:00.000Z PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 https://www.biopharmawatch.com/news/CTMX/cytomx-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-30T12:00:00.000Z Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/VCEL/vericel-reports-q2-2026-results-guidance-share-repurchase BiopharmaWatch en 2026-07-30T11:55:00.000Z Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-q2-2026-results-highlights BiopharmaWatch en 2026-07-30T11:35:00.000Z Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/DGX/bacterial-vaginosis-sti-co-infection-quest-diagnostics BiopharmaWatch en 2026-07-30T11:30:00.000Z Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-fda-workshop-drug-repurposing BiopharmaWatch en 2026-07-30T11:30:00.000Z Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing https://www.biopharmawatch.com/news/IFRX/inflarx-report-q2-2026-results-august-6 BiopharmaWatch en 2026-07-30T11:30:00.000Z InflaRx to Report Second Quarter 2026 Results on August 6, 2026 https://www.biopharmawatch.com/news/TVRD/tvardi-therapeutics-ulcerative-colitis-tti-109 BiopharmaWatch en 2026-07-30T11:30:00.000Z Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 https://www.biopharmawatch.com/news/WVE/wave-life-sciences-q2-2026-financial-results-update BiopharmaWatch en 2026-07-30T11:30:00.000Z Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/SIGA/siga-business-update-call-august-2026 BiopharmaWatch en 2026-07-30T11:30:00.000Z SIGA to Host Business Update Call on August 6, 2026, Following Release of Second-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-q4-fy26-cash-flow-report BiopharmaWatch en 2026-07-30T11:25:00.000Z Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update https://www.biopharmawatch.com/news/BAX/baxter-reports-second-quarter-2026-results BiopharmaWatch en 2026-07-30T11:15:00.000Z Baxter Reports Second-Quarter 2026 Results https://www.biopharmawatch.com/news/USNA/usana-glow-consumer-study-results BiopharmaWatch en 2026-07-30T11:04:00.000Z New 12-Week Consumer Study Highlights Visible Skin Benefits with USANA Glow https://www.biopharmawatch.com/news/BEAT/heartbeam-second-quarter-2026-results-conference-call BiopharmaWatch en 2026-07-30T11:00:00.000Z HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time https://www.biopharmawatch.com/news/HSIC/henry-schein-leadership-transitions BiopharmaWatch en 2026-07-30T11:00:00.000Z Henry Schein Announces Leadership Transitions https://www.biopharmawatch.com/news/BCYC/bicycle-therapeutics-q2-2026-results BiopharmaWatch en 2026-07-30T11:00:00.000Z Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NVAX/novavax-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-30T11:00:00.000Z Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026 https://www.biopharmawatch.com/news/IMCR/immunocore-q2-2026-financial-results-call BiopharmaWatch en 2026-07-30T11:00:00.000Z Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 https://www.biopharmawatch.com/news/XAIR/beyond-air-announces-private-placement-offering BiopharmaWatch en 2026-07-30T11:00:00.000Z Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-30T11:00:00.000Z Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/EYPT/eyepoint-completes-enrollment-phase-3-trials-duravyu-dme BiopharmaWatch en 2026-07-30T11:00:00.000Z EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME) https://www.biopharmawatch.com/news/INMB/inmune-bio-scientific-advisory-board-cordstrom-development BiopharmaWatch en 2026-07-30T11:00:00.000Z INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-q2-financial-results-2026 BiopharmaWatch en 2026-07-30T10:59:00.000Z Bristol Myers Squibb Reports Second Quarter Financial Results for 2026 https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-07-30T10:59:00.000Z Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LH/labcorp-2026-second-quarter-results-guidance-update BiopharmaWatch en 2026-07-30T10:50:00.000Z Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance https://www.biopharmawatch.com/news/PFE/pfizer-positive-topline-phase-3-results-litfulo-vitiligo BiopharmaWatch en 2026-07-30T10:45:00.000Z Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo https://www.biopharmawatch.com/news/BFLY/butterfly-network-q2-2026-results BiopharmaWatch en 2026-07-30T10:30:00.000Z Butterfly Network Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STVN/liraglutide-combination-products-stevanato-europe BiopharmaWatch en 2026-07-30T10:30:00.000Z Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries https://www.biopharmawatch.com/news/CYTK/cytokinetics-mhra-authorization-aficamten-nice-guidance BiopharmaWatch en 2026-07-30T10:20:00.000Z Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales https://www.biopharmawatch.com/news/TAK/takeda-fy2026-q1-results-launch-preparations-pipeline-progress BiopharmaWatch en 2026-07-30T06:37:00.000Z Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track https://www.biopharmawatch.com/news/CGON/bcan-think-tank-2026-creto-eap-poster-podium BiopharmaWatch en 2026-07-30T06:29:00.000Z BCAN Think Tank 2026 – Creto EAP Poster and Podium https://www.biopharmawatch.com/news/PHAR/pharming-q2-2026-financial-results-guidance-revision BiopharmaWatch en 2026-07-30T05:00:00.000Z Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use https://www.biopharmawatch.com/news/MESO/mesoblast-ryoncil-revenue-growth-expansion BiopharmaWatch en 2026-07-30T00:57:00.000Z Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch https://www.biopharmawatch.com/news/INO/inovio-announces-public-offering-pricing BiopharmaWatch en 2026-07-30T00:53:00.000Z INOVIO Announces Pricing of $20.0 Million Public Offering https://www.biopharmawatch.com/news/ALGN/align-technology-2026-invisalign-ortho-summit BiopharmaWatch en 2026-07-29T22:45:00.000Z Align Technology Hosts 2026 Invisalign® Ortho Summit, Showcasing a “Beyond Possible” Vision for Connected Digital Orthodontics https://www.biopharmawatch.com/news/IBRX/immunitybio-uae-marketing-authorization-anktiva BiopharmaWatch en 2026-07-29T22:45:00.000Z ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/ARAY/accuray-financial-strengthening-strategic-partnerships BiopharmaWatch en 2026-07-29T22:26:00.000Z Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation https://www.biopharmawatch.com/news/JNJ/johnson-johnson-acquisition-firefly-bio-oncology BiopharmaWatch en 2026-07-29T21:42:00.000Z Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation https://www.biopharmawatch.com/news/GCTK/lokahi-therapeutics-lt-100-single-injection-strategy BiopharmaWatch en 2026-07-29T21:30:00.000Z Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration https://www.biopharmawatch.com/news/JNJ/jnj-collaboration-sail-biomedicines-car-t-therapies BiopharmaWatch en 2026-07-29T21:28:00.000Z Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset https://www.biopharmawatch.com/news/ALGN/align-technology-strategic-initiatives-growth BiopharmaWatch en 2026-07-29T20:45:00.000Z Align Technology Announces Strategic Initiatives Consistent with Long-term Growth and Shareholder Value Creation Objectives https://www.biopharmawatch.com/news/ALGN/align-technology-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:36:00.000Z Align Technology Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-q2-2026-results-announcement BiopharmaWatch en 2026-07-29T20:31:00.000Z Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/PFE/european-commission-authorizes-pfizer-biontech-xfg-vaccine BiopharmaWatch en 2026-07-29T20:30:00.000Z European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union https://www.biopharmawatch.com/news/BNTX/eu-commission-approves-biontech-covid-vaccine-xfg-variant BiopharmaWatch en 2026-07-29T20:30:00.000Z Europäische Kommission genehmigt Marktzulassung des an XFG angepassten COVID-19-Impfstoffs von Pfizer und BioNTech in der Europäischen Union https://www.biopharmawatch.com/news/BNTX/european-commission-authorizes-biontech-covid-vaccine BiopharmaWatch en 2026-07-29T20:30:00.000Z European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:30:00.000Z Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/UFPT/ufp-technologies-second-quarter-2026-results BiopharmaWatch en 2026-07-29T20:20:00.000Z UFP Technologies to Report Second Quarter 2026 Financial Results on August 3, 2026 https://www.biopharmawatch.com/news/TFX/teleflex-fda-approval-ezplaz-freeze-dried-plasma BiopharmaWatch en 2026-07-29T20:15:00.000Z Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma https://www.biopharmawatch.com/news/MDAI/spectral-ai-schedules-2026-q2-financial-results-call BiopharmaWatch en 2026-07-29T20:15:00.000Z Spectral AI Schedules 2026 Second Quarter Financial Results and Conference Call https://www.biopharmawatch.com/news/HCTI/hcti-acquires-cosmoinnovations-medtech-market BiopharmaWatch en 2026-07-29T20:10:00.000Z Healthcare Triangle Signs Non-Binding LOI to Acquire 51% of CosmoInnovations; Enters High-Growth Proprietary MedTech and Consumer-Health Markets https://www.biopharmawatch.com/news/MDXG/mimedx-second-quarter-2026-results BiopharmaWatch en 2026-07-29T20:07:00.000Z MIMEDX Announces Second Quarter 2026 Operating & Financial Results https://www.biopharmawatch.com/news/KRMD/koru-medical-participate-canaccord-genuity-conference BiopharmaWatch en 2026-07-29T20:05:00.000Z KORU Medical Systems to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/GKOS/glaukos-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:05:00.000Z Glaukos Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TLSI/trisalus-life-sciences-canaccord-growth-conference BiopharmaWatch en 2026-07-29T20:05:00.000Z TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-q2-financial-results-update BiopharmaWatch en 2026-07-29T20:05:00.000Z Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/MYO/myomo-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-29T20:05:00.000Z Myomo to Report Second Quarter 2026 Financial Results on August 5 https://www.biopharmawatch.com/news/CNMD/conmed-corporation-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:05:00.000Z CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance https://www.biopharmawatch.com/news/SI/shoulder-innovations-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-07-29T20:05:00.000Z Shoulder Innovations to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/TDOC/teladoc-health-q2-2026-results BiopharmaWatch en 2026-07-29T20:05:00.000Z Teladoc Health Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/ADPT/adaptive-biotechnologies-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:05:00.000Z Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TELA/tela-bio-participate-canaccord-growth-conference BiopharmaWatch en 2026-07-29T20:05:00.000Z TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:05:00.000Z Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 https://www.biopharmawatch.com/news/KIDS/orthopediatrics-participate-canaccord-growth-conference BiopharmaWatch en 2026-07-29T20:05:00.000Z OrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/RVMD/revolution-medicines-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:05:00.000Z Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 https://www.biopharmawatch.com/news/SERA/sera-prognostics-conference-call-q2-2026-results BiopharmaWatch en 2026-07-29T20:05:00.000Z SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026 https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-07-29T20:05:00.000Z Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-babesiosis-study-enrollment BiopharmaWatch en 2026-07-29T20:03:00.000Z 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 https://www.biopharmawatch.com/news/BBNX/beta-bionics-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:02:00.000Z Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-q2-2026-financial-results-call BiopharmaWatch en 2026-07-29T20:01:00.000Z Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 https://www.biopharmawatch.com/news/XNCR/xencor-alexion-ultomiris-royalty-settlement BiopharmaWatch en 2026-07-29T20:01:00.000Z Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter https://www.biopharmawatch.com/news/GRAL/grail-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-29T20:01:00.000Z GRAIL to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SMTI/mimedx-acquire-sanara-medtech BiopharmaWatch en 2026-07-29T20:01:00.000Z MIMEDX to Acquire Sanara MedTech https://www.biopharmawatch.com/news/IVA/inventiva-preliminary-financial-results-h1-2026 BiopharmaWatch en 2026-07-29T20:00:00.000Z Inventiva Announces Preliminary Financial Results for the First Half of 2026¹ https://www.biopharmawatch.com/news/AVNS/sterlington-advises-avanos-medical-acquisition BiopharmaWatch en 2026-07-29T19:14:00.000Z Sterlington Advises Avanos Medical Management Team on $1.27 Billion Acquisition https://www.biopharmawatch.com/news/ENTX/entera-bio-275m-pipe-financing BiopharmaWatch en 2026-07-29T19:00:00.000Z Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE https://www.biopharmawatch.com/news/HIMS/hims-responds-ftc-lawsuit BiopharmaWatch en 2026-07-29T17:51:00.000Z Hims & Hers Responds to FTC Lawsuit https://www.biopharmawatch.com/news/CMPS/compass-pathways-q2-2026-financial-results BiopharmaWatch en 2026-07-29T17:02:00.000Z Samenvatting: Compass Pathways maakt op 5 augustus 2026 de financiële resultaten over het tweede kwartaal en de eerste helft van 2026 bekend https://www.biopharmawatch.com/news/CMPS/compass-pathways-financial-results-august-2026 BiopharmaWatch en 2026-07-29T17:02:00.000Z Compass Pathways gibt am 5. August 2026 die Finanzergebnisse für das zweite Quartal und das erste Halbjahr 2026 bekannt https://www.biopharmawatch.com/news/HCSG/arizona-children-hearing-loss-intervention-services BiopharmaWatch en 2026-07-29T16:38:00.000Z More Arizona Children with Hearing Loss to Benefit from Expanded Early Intervention and Hearing Healthcare Services https://www.biopharmawatch.com/news/INCY/opzelura-ruxolitinib-goedkeuring-eu BiopharmaWatch en 2026-07-29T16:20:00.000Z Samenvatting: Opzelura® (ruxolitinib) crème wordt de eerste topische JAK-remmer zonder steroïden die in de Europese Unie is goedgekeurd voor volwassenen met matig ernstige atopische dermatitis https://www.biopharmawatch.com/news/INCY/opzelura-approval-jak-inhibitor-dermatite-atopica BiopharmaWatch en 2026-07-29T16:20:00.000Z Riassunto: Opzelura® (ruxolitinib) crema diventa il primo inibitore mirato di JAK privo di steroidi approvato nell'Unione europea per adulti con dermatite atopica moderata https://www.biopharmawatch.com/news/INCY/opzelura-ruxolitinib-cream-eu-approval BiopharmaWatch en 2026-07-29T16:19:00.000Z Opzelura® (Ruxolitinib)-Creme ist der erste steroidfreie topische JAK-Hemmer, der in der Europäischen Union für Erwachsene mit mittelschwerer atopischer Dermatitis zugelassen wurde https://www.biopharmawatch.com/news/OM/outset-medical-insiders-fiduciary-duties BiopharmaWatch en 2026-07-29T15:19:00.000Z Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders? https://www.biopharmawatch.com/news/MRK/merck-announces-fourth-quarter-2026-dividend BiopharmaWatch en 2026-07-29T15:04:00.000Z Merck Announces Fourth-Quarter 2026 Dividend https://www.biopharmawatch.com/news/IGC/igc-pharma-evaluates-recovery-options-jury-verdict BiopharmaWatch en 2026-07-29T14:40:00.000Z IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign https://www.biopharmawatch.com/news/HYPD/hyperion-defi-q2-earnings-call-2026 BiopharmaWatch en 2026-07-29T14:21:00.000Z Hyperion DeFi Schedules First Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET https://www.biopharmawatch.com/news/CAPR/lancet-publishes-hope-3-data-capricor-deramiocel BiopharmaWatch en 2026-07-29T14:05:00.000Z The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy https://www.biopharmawatch.com/news/SNN/smith-nephew-tessa-surgery-system-fda-approval BiopharmaWatch en 2026-07-29T14:00:00.000Z Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation https://www.biopharmawatch.com/news/BFLY/science-corp-names-nevada-sanchez-evp-engineering BiopharmaWatch en 2026-07-29T14:00:00.000Z Science Corp. Names Nevada Sanchez as Executive Vice President of Engineering https://www.biopharmawatch.com/news/UNH/unitedhealth-expands-health-hubs-tennessee BiopharmaWatch en 2026-07-29T13:38:00.000Z UnitedHealth Group Partners with UT Health Sciences to Expand Health Hubs to More Communities Across Tennessee https://www.biopharmawatch.com/news/ALVO/alvotech-fda-inspection-closure-reykjavik BiopharmaWatch en 2026-07-29T13:32:00.000Z Alvotech announces successful closure of FDA inspection of manufacturing facility https://www.biopharmawatch.com/news/HCWB/hcw-biologics-private-placement-offering BiopharmaWatch en 2026-07-29T13:06:00.000Z HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering https://www.biopharmawatch.com/news/HSCS/heartsciences-fortitude-mining-combination-update BiopharmaWatch en 2026-07-29T13:00:00.000Z HeartSciences Files Preliminary Proxy Statement for Business Combination with Fortitude Mining Holdings; Provides Business Update and Reports Fiscal 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/chmp-positive-opinion-amgen-repatha-heart-attack-stroke BiopharmaWatch en 2026-07-29T13:00:00.000Z POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE https://www.biopharmawatch.com/news/FMS/fresenius-beacon-us-hd-hemodiafiltration BiopharmaWatch en 2026-07-29T13:00:00.000Z Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients https://www.biopharmawatch.com/news/TXG/10x-genomics-lausanne-university-hospital-collaboration-cancer BiopharmaWatch en 2026-07-29T13:00:00.000Z 10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Care https://www.biopharmawatch.com/news/SPRC/scisparc-neurothera-quantum-platform-validation BiopharmaWatch en 2026-07-29T12:32:00.000Z SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company https://www.biopharmawatch.com/news/QTI/qt-imaging-appoints-dr-julia-albright-cso BiopharmaWatch en 2026-07-29T12:30:00.000Z QT Imaging Appoints Medical Imaging and Digital Health Executive Dr. Julia Albright as Chief Science Officer https://www.biopharmawatch.com/news/ACOG/alpha-cognition-european-patent-zunveyl-alzheimers BiopharmaWatch en 2026-07-29T12:30:00.000Z Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease https://www.biopharmawatch.com/news/PRGO/perrigo-present-canaccord-annual-growth-conference BiopharmaWatch en 2026-07-29T12:30:00.000Z Perrigo to Present at the Canaccord 46th Annual Growth Conference https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-fda-rmat-designation-cema-cel BiopharmaWatch en 2026-07-29T12:30:00.000Z Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma https://www.biopharmawatch.com/news/BVS/bioventus-second-quarter-fiscal-year-2026-results BiopharmaWatch en 2026-07-29T12:30:00.000Z Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/GRFS/foxos-vector-acquires-blood-collection-centers BiopharmaWatch en 2026-07-29T12:30:00.000Z FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC. https://www.biopharmawatch.com/news/PYPD/polypid-fda-acceptance-nda-priority-review-d-plex-100 BiopharmaWatch en 2026-07-29T12:30:00.000Z PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-29T12:30:00.000Z CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 https://www.biopharmawatch.com/news/RNXT/renovorx-q2-2026-financial-results-conference-call BiopharmaWatch en 2026-07-29T12:30:00.000Z RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET https://www.biopharmawatch.com/news/CLNN/clene-presentation-canaccord-growth-conference BiopharmaWatch en 2026-07-29T12:30:00.000Z Clene to Present at The Canaccord 46th Annual Growth Conference https://www.biopharmawatch.com/news/CADL/candel-therapeutics-presentation-canaccord-conference BiopharmaWatch en 2026-07-29T12:16:34.761Z Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston https://www.biopharmawatch.com/news/URGN/urogen-pharma-q2-2026-financial-results BiopharmaWatch en 2026-07-29T12:16:07.891Z UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 https://www.biopharmawatch.com/news/ENLV/enlivex-webinar-capital-strategy-clinical-milestones BiopharmaWatch en 2026-07-29T12:14:02.073Z Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones https://www.biopharmawatch.com/news/TVGN/tevogen-bio-holdings-becomes-tevogen-inc BiopharmaWatch en 2026-07-29T12:13:45.234Z Tevogen Bio Holdings Inc. Becomes Tevogen Inc. https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-announces-150-million-private-placement BiopharmaWatch en 2026-07-29T12:13:29.385Z LB Pharmaceuticals Announces $150 Million Private Placement https://www.biopharmawatch.com/news/AKBA/akebia-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-29T12:13:08.471Z Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-day-2026 BiopharmaWatch en 2026-07-29T12:12:29.630Z NewAmsterdam Pharma to Host Investor Day on August 5, 2026 https://www.biopharmawatch.com/news/A/agilent-research-catalyst-award-eastern-institute-technology BiopharmaWatch en 2026-07-29T12:00:00.000Z Agilent Research Catalyst Award Presented to Eastern Institute of Technology, Ningbo https://www.biopharmawatch.com/news/SRRK/scholar-rock-presents-canaccord-growth-conference-2026 BiopharmaWatch en 2026-07-29T12:00:00.000Z Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-baylor-scott-white-research-institute BiopharmaWatch en 2026-07-29T12:00:00.000Z Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma https://www.biopharmawatch.com/news/MDWD/mediwound-report-second-quarter-2026-results BiopharmaWatch en 2026-07-29T12:00:00.000Z MediWound to Report Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FLNA/filana-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-07-29T12:00:00.000Z Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MRK/bacterial-vaginosis-merck-manuals-women-partners BiopharmaWatch en 2026-07-29T12:00:00.000Z Bacterial Vaginosis: Merck Manuals Shares What Women and Partners Need to Know https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-conference-call-q2-2026 BiopharmaWatch en 2026-07-29T11:30:00.000Z TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/PCSA/processa-acquisition-vidya-therapeutics-btk-inhibitor BiopharmaWatch en 2026-07-29T11:30:00.000Z PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS https://www.biopharmawatch.com/news/BWAY/brainsway-report-second-quarter-2026-results BiopharmaWatch en 2026-07-29T11:30:00.000Z BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026 https://www.biopharmawatch.com/news/ACON/aclarion-ceo-shareholder-letter-progress-2026 BiopharmaWatch en 2026-07-29T11:22:04.571Z Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 https://www.biopharmawatch.com/news/CBLL/ceribell-expands-board-directors-west-okeefe BiopharmaWatch en 2026-07-29T11:21:33.258Z Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe https://www.biopharmawatch.com/news/QURE/uniqure-q2-2026-financial-results-update BiopharmaWatch en 2026-07-29T11:18:14.698Z uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update https://www.biopharmawatch.com/news/AXGN/trace-biosciences-axogen-investment-nerve-trace-technology BiopharmaWatch en 2026-07-29T11:10:00.000Z Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology https://www.biopharmawatch.com/news/IONS/ionis-frank-bennett-retirement-announcement BiopharmaWatch en 2026-07-29T11:05:00.000Z Ionis announces Dr. Frank Bennett, chief scientific officer, to retire https://www.biopharmawatch.com/news/AXGN/axogen-reports-q2-2026-financial-results BiopharmaWatch en 2026-07-29T11:05:00.000Z Axogen, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/OCGN/ocugen-fda-rmat-designation-ocu410-geographic-atrophy BiopharmaWatch en 2026-07-29T11:01:00.000Z Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration https://www.biopharmawatch.com/news/OPCH/option-care-health-q2-2026-financial-results BiopharmaWatch en 2026-07-29T11:00:00.000Z Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-nanopulse-af-study-enrollment-midpoint BiopharmaWatch en 2026-07-29T11:00:00.000Z Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q2-2026-earnings-call BiopharmaWatch en 2026-07-29T11:00:00.000Z National Vision Holdings, Inc. Announces Second Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/IONS/ionis-q2-2026-financial-results-tryngolza-launch BiopharmaWatch en 2026-07-29T11:00:00.000Z Ionis reports second quarter 2026 financial results and highlights progress on key programs https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-phase-2-3-trial-sil204 BiopharmaWatch en 2026-07-29T11:00:00.000Z Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center https://www.biopharmawatch.com/news/XRTX/xortx-appoints-new-director BiopharmaWatch en 2026-07-29T11:00:00.000Z XORTX Appoints New Director https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-share-issuances-nasdaq-compliance BiopharmaWatch en 2026-07-29T11:00:00.000Z Healthcare Triangle Completes Share Issuances Relating to Legacy M&A Transactions, Strengthening Compliance With Nasdaq's New $5 Million Market Value Listing Standard https://www.biopharmawatch.com/news/CALC/calcimedica-fda-alignment-phase-2b-trial-auxora BiopharmaWatch en 2026-07-29T11:00:00.000Z CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q2-2026-earnings-call-date BiopharmaWatch en 2026-07-29T11:00:00.000Z Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q2-2026-results-conference-call BiopharmaWatch en 2026-07-29T11:00:00.000Z Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-strengthens-patent-portfolio BiopharmaWatch en 2026-07-29T11:00:00.000Z VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates https://www.biopharmawatch.com/news/ADMA/adma-biologics-second-quarter-2026-results BiopharmaWatch en 2026-07-29T11:00:00.000Z ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-first-patient-dosed-phase-3-alloha-2 BiopharmaWatch en 2026-07-29T11:00:00.000Z TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies https://www.biopharmawatch.com/news/AMRN/amarin-q2-2026-financial-results BiopharmaWatch en 2026-07-29T11:00:00.000Z Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence https://www.biopharmawatch.com/news/VTRS/viatris-fda-approval-gwyn-lo-contraceptive-patch BiopharmaWatch en 2026-07-29T10:59:00.000Z Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch https://www.biopharmawatch.com/news/BLCO/bausch-lomb-second-quarter-growth-2026 BiopharmaWatch en 2026-07-29T10:58:00.000Z Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance https://www.biopharmawatch.com/news/BDX/bdx-semaglutide-launch-brazil BiopharmaWatch en 2026-07-29T10:54:00.000Z EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-khindivi-indication-expansion BiopharmaWatch en 2026-07-29T10:50:00.000Z Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution https://www.biopharmawatch.com/news/UTHR/united-therapeutics-advance-outcomes-study-ralinepag BiopharmaWatch en 2026-07-29T10:30:00.000Z United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet https://www.biopharmawatch.com/news/CMPS/compass-pathways-q2-2026-financial-results-announcement BiopharmaWatch en 2026-07-29T10:30:00.000Z Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/BSX/boston-scientific-q2-2026-results BiopharmaWatch en 2026-07-29T10:30:00.000Z Boston Scientific announces results for second quarter 2026 https://www.biopharmawatch.com/news/FTRE/fortrea-reports-q2-2026-results BiopharmaWatch en 2026-07-29T10:30:00.000Z Fortrea Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/MNKD/mannkind-positive-phase-1b-inflo-1-results BiopharmaWatch en 2026-07-29T10:30:00.000Z MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF https://www.biopharmawatch.com/news/GEHC/ge-healthcare-q2-2026-financial-results BiopharmaWatch en 2026-07-29T10:20:00.000Z GE HealthCare reports second quarter 2026 financial results https://www.biopharmawatch.com/news/AVTR/avantor-reports-q2-2026-results BiopharmaWatch en 2026-07-29T10:05:00.000Z Avantor® Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/AMPH/amphastar-pharmaceuticals-q2-2026-earnings-call BiopharmaWatch en 2026-07-29T10:00:00.000Z Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 https://www.biopharmawatch.com/news/IART/integra-lifesciences-q2-2026-financial-results BiopharmaWatch en 2026-07-29T10:00:00.000Z Integra LifeSciences Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MRK/evinova-merck-partnership-clinical-development BiopharmaWatch en 2026-07-29T08:00:00.000Z Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development https://www.biopharmawatch.com/news/ABBV/abbvie-eu-approval-rinvoq-alopecia-areata BiopharmaWatch en 2026-07-29T07:00:00.000Z AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata https://www.biopharmawatch.com/news/ABBV/abbvie-approval-rinvoq-non-segmental-vitiligo BiopharmaWatch en 2026-07-29T07:00:00.000Z AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo https://www.biopharmawatch.com/news/YDES/yd-bio-numia-health-cancer-testing-pilot BiopharmaWatch en 2026-07-29T03:19:28.000Z YD Bio 與 Numia Health 啟動跨境癌症檢測試辦計畫，評估拓展加拿大分子診斷服務之可行性 https://www.biopharmawatch.com/news/BHC/bausch-health-q2-2026-results-guidance BiopharmaWatch en 2026-07-29T00:00:00.000Z BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE Second Quarter Consolidated Revenues of $2.85 billion, up 13% on a Reported basis and 11% on an Organic (non-GAAP)1 basis over the prior year period... https://www.biopharmawatch.com/news/NKTR/nektar-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-28T22:00:00.000Z Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets https://www.biopharmawatch.com/news/SEER/seer-stockholders-re-elect-director-nominees-2026 BiopharmaWatch en 2026-07-28T21:40:00.000Z Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting https://www.biopharmawatch.com/news/HCAT/health-catalyst-q2-2026-results-conference-call BiopharmaWatch en 2026-07-28T21:30:00.000Z Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026